n adult-onset moyamoya disease, intracranial hemorrhage accounts for one half of primary manifestations. The rebleeding rate (bleeding rate after initial bleeding) is ≈7% per year, and the outcome after rebleeding is poor. 1 The Japan Adult Moyamoya (JAM) Trial, a multicenter randomized controlled trial, was conducted to determine whether direct bypass surgery reduces rebleeding in adult-onset hemorrhagic moyamoya disease. The published primary results support this hypothesis.
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January 2016 bleeding site at onset through classification as either anterior or posterior determined before randomization. This subgroup analysis is intended to test the above prespecified hypothesis about hemorrhagic moyamoya disease: that the anterior and posterior hemorrhage groups differ in terms of the outcome of nonsurgical treatment and the effect of bypass surgery at preventing rebleeding.
Methods
The design of the JAM Trial has been described elsewhere. 2, 8 In brief, participants were recruited from 22 centers specializing in moyamoya disease. Patients with moyamoya disease were eligible if they had suffered intracranial hemorrhage within the 12 months before randomization, were aged 16 to 65 years, were independent in daily life (0-2 for modified Rankin Scale score), had completed acute phase treatment at least 1 month before randomization, and had been free from ischemic/hemorrhagic attack for at least 1 month. Diagnoses of moyamoya disease were made according to the proposed criteria. 9 Participants were randomly allocated to either the surgical or the nonsurgical group. Stratified randomization according to hemorrhagic site was adopted, as described later. Those in the surgical group required direct bypass surgery, including superficial temporal arterymiddle cerebral artery anastomosis, within 3 months of randomization in addition to medical treatment, and those in the nonsurgical group underwent medical treatment alone. The primary end points were defined as any of the following events: a rebleeding attack, completed stroke resulting in significant morbidity, significant morbidity or mortality from any medical cause, or requirement for bypass surgery for a nonsurgical patient as determined by a registered neurologist. The secondary end point was defined as a rebleeding attack. Both a neurologist and a neurosurgeon followed each participant in each participating institute for 5 years or until end points were reached. Although antihypertensive medication was administrated to patients with hypertension, the use of anticoagulants or antiplatelet drugs was prohibited. The patients' medical, neurological, radiological, and functional conditions were closely monitored and reported annually. The study was approved by the ethical committees of all participating centers and was registered with the University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR, ID: C000000166, 2005).
Subgroup of Interest
Hemorrhagic site was the only stratifying variable for randomization. The study protocol allowed for analyses of the subgroup in advance. Before randomization, the study office classified the hemorrhage at onset in each participant as either anterior or posterior according to the center location of the intracerebral hemorrhage as observed in computed tomographic images (Figure 1 ; Figures I-IV in the onlineonly Data Supplement). An anterior hemorrhage was defined as one attributable to perforating arteries from the anterior or middle cerebral artery, including those located in the putamen, caudate head, frontal lobe, anterior half of the temporal lobe, subependymal area of the anterior part of the lateral ventricle, or anterior half of the corpus callosum. A posterior hemorrhage was defined as one attributable to perforating arteries from the posterior cerebral artery or choroidal arteries, including those located in the thalamus, posterior half of the temporal lobe, parietal lobe, occipital lobe, subependymal area of the posterior part of the lateral ventricle including the trigon, or posterior half of the corpus callosum. Primary intraventricular hemorrhage, defined as intraventricular hemorrhage without intraparenchymal hemorrhage, was classified as either anterior or posterior according to the distribution of hematoma ( Figure 1A ). Any diffusely distributed primary intraventricular hemorrhage whose origin was difficult to determine was classified as anterior. Subarachnoid hemorrhage without intracerebral hemorrhage was classified in a similar fashion ( Figure 1A ).
Statistical Analysis
All analyses were performed according to the intention-to-treat principle. Kaplan-Meier survival analysis and Cox proportional hazard model were used to compare the incidence of the end points in each subgroup. The assessment of effect modification (heterogeneity of 
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January 2016 treatment effect) was focused on the hemorrhagic site subgroup because the sample size was insufficient to allow the assessment across all baseline subgroups. Effect modification was tested by Cox proportional hazards analyses incorporating the interaction term and was presented as a P value for interaction. We also analyzed effect modification for the other baseline variables: age (with the median as the cutoff point), sex, hypertension, and hemorrhage type. Reproducibility of the classification as anterior or posterior hemorrhage was assessed by a panel assembled for this analysis, and agreement was expressed as the κ coefficient. Sensitivity analysis based on the panel classification was also performed. Two-sided values of P<0.05 were considered significant. All analyses were performed with IBM SPSS software, version 20 (IBM Software Group, Chicago, IL).
Results
Of the 80 patients enrolled in total, 42 were assigned to the surgical group and 38 to the nonsurgical group. Patient demographics for both the groups were comparable as described in the published article. As a result of stratified randomization, the numbers of patients with anterior or posterior hemorrhage were similar in the surgical and nonsurgical groups; the surgical group included 24 patients with anterior hemorrhage (57.1%) and 18 with posterior hemorrhage (42.9%), whereas the nonsurgical group included 21 patients with anterior hemorrhage (55.3%) and 17 with posterior hemorrhage (44.7%). The classifications of anterior and posterior hemorrhage showed almost perfect inter-rater agreement (κ=0.82; 95% confidence interval [CI], 0.70-0.95).
Surgical Effects by Hemorrhagic Site
The effect of bypass surgery on the event rate was varied by the hemorrhagic site. About the primary end point, the hazard ratio (HR) for the surgical group relative to the nonsurgical group was 0.07 (95% CI, 0.01-0.55) for the posterior group, whereas the ratio exceeded 1 in the anterior group (HR, 1.62; 95% CI, 0.39-6.79), with P=0.013 for interaction (Table 1; Figure 2 ); this indicates that significant effect modification was observed. About the secondary end point, the similar effect modification was apparent as shown in the KaplanMeier curves (Figure 2 ). Calculation of either the HR or the interaction P value was impossible for the secondary end point because the event rate was zero in the surgical group within the posterior hemorrhage strata. The HR was not substantially influenced by age, sex, presence of hypertension, or type of hemorrhage ( Table 1) . The results of the sensitivity analysis are shown in Table I in the online-only Data Supplement.
Analysis of the Nonsurgical Group
The analysis was then limited to the nonsurgical group, which comprised 38 patients (21 with anterior hemorrhage and 17 Figure 2 . Kaplan-Meier estimates of the incidence of primary and secondary end points by hemorrhagic site. P=0.013 for interaction in the primary end point. Calculation of the hazard ratio (HR) and interaction P value was impossible for the secondary end point. with posterior hemorrhage). Overall 5-year risk and annual incidence of rebleeding were 31.6% (12/38) and 7.6%, respectively. Baseline characteristics such as age, sex, coexisting disease, history of hemorrhagic or ischemic stroke, and type of hemorrhage were not significantly different between anterior and posterior groups ( Table 2 ). The incidence rates for both the primary and secondary end points were significantly higher for the posterior group than for the anterior group (P=0.003 and 0.001 for log-rank test, respectively; Figure 3 ). The annual incidence rate for the primary end point was as high as 17.1% per year for the posterior group, as compared with 3.0% per year for the anterior group. The HR for posterior hemorrhage relative to anterior hemorrhage was 5.83 (95% CI, 1.60-21.27) for the primary end point and 8.52 (95% CI, 1.86-39.02) for the secondary end point. No other baseline factor was significantly associated with the incidence of end points in the univariate analysis (Table 3) , and no further multivariate analysis was performed. The results of the sensitivity analysis are shown in Table II in the online-only Data Supplement.
Analysis of the Surgical Group
The Kaplan-Meier analysis within the surgical group revealed that the incidence rate for the secondary end points was significantly higher for the anterior group than for the posterior group (P=0.045), indicating a tendency opposite to that revealed in the analysis of the nonsurgical group.
Discussion Rebleeding Risk by Hemorrhagic Site
Our results suggest that the posterior hemorrhage group is, by its nature, at higher risk of rebleeding than the anterior group. Previous observational studies have identified only a few risk factors associated with rebleeding, including age at onset and the presence of silent cerebral microbleeds, 10, 11 and have rarely addressed the bleeding site in the manner of this study. Only Kobayashi et al 1 reported a higher incidence of rebleeding in patients with thalamic hemorrhage compared with those with basal ganglia hemorrhage, although their definition of hemorrhagic site differed from ours.
The high incidence of rebleeding in the posterior hemorrhage group can be explained by the vascular morphology of moyamoya disease, which has recently received more attention. As shown in the outstanding work of Morioka et al, 4 dilated and extended choroidal or thalamic perforating arteries seem more responsible for bleeding than do the tiny vessels that proliferate from the lenticulostriate artery, which have traditionally been denoted as moyamoya vessels and suspected as source of bleeding. In moyamoya disease, the anterior choroidal artery can form abnormal anastomoses of the medullary artery around the trigon of the lateral ventricle, where bleeding can occur. 12 The dilatation and extension of the perforators from the posterior communicating artery create a risk of bleeding in the thalamus. 4 Other thalamic perforators can also proliferate, especially when the posterior cerebral artery is occluded. 13 All bleeding from these fragile collaterals could be commonly classified as posterior hemorrhage; for this reason, the rebleeding risk of the posterior group might have been elevated.
However, the causes of anterior hemorrhage might be heterogeneous because, by definition, it includes hemorrhage of 
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unknown origin. The lenticulostriate arteries, possible sources of anterior hemorrhage, might suffer less hemodynamic stress than the choroidal or thalamic arteries as long as the terminal portion of the internal carotid artery has narrowed. These points of speculation should be confirmed through further analysis.
Surgical Effects by Hemorrhagic Site
Our results suggest that patients with posterior hemorrhage accrue greater surgical benefit than those with anterior hemorrhage. No previous study, to the best of our knowledge, has focused on the effect modification by hemorrhagic site. Our results seem valid because biases were minimized through the prospective design of the study and the determination to analyze a prespecified (versus post hoc) subgroup. This result might reflect the different natures of the anterior and posterior hemorrhage groups, as discussed above. The abnormal collaterals formed by the thalamic or choroidal arteries, possible sources of posterior hemorrhage, can connect to the middle cerebral artery in the cortex via the medullary artery. 3, 12 Direct bypass, introduced in the territory of the middle cerebral artery, might eliminate hemorrhagic stress on the collaterals by augmenting blood flow in that very area. Kuroda et al 7 reported the elimination of peripheral aneurysms after bypass surgery, all of which had formed in the thalamic or choroidal artery. A more recent report, revealing that the dilatation and extension of the choroidal and thalamic arteries was likely to diminish after bypass surgery, 14 also supports this speculation. The degree of preoperative perfusion impairment or postoperative improvement might differ between the anterior and posterior groups and should also be analyzed in further studies.
As shown in this analysis, higher rebleeding risk and greater surgical effects in the posterior hemorrhage group might, after careful interpretation, provide valuable information on the treatment of hemorrhagic moyamoya disease. Although the efficacy of bypass surgery was confirmed in the overall comparison of the JAM Trial, 2 identification of a more beneficial subgroup is required, considering the potential invasiveness of surgery. Patients with posterior hemorrhage might comprise a more optimal target group for bypass surgery. Further studies, along with the present result, might reveal optimal indications for bypass surgery in the future.
Limitations
This study has several limitations. First, although the JAM Trial is the only randomized controlled trial for moyamoya disease, the sample size was relatively small because of the low prevalence of the disease; this resulted in the wide CIs observed in the results. Second, a type I error could have contaminated the credibility of the subgroup results, even if multiple comparisons were carefully avoided by restricting the focus on the predetermined subgroup. Third, potential misclassification of the hemorrhagic site could have affected the results, although the results of the sensitivity analysis correspond closely to those of the primary analysis and seem to support the conclusion. Further prospective studies, as well as subgroup analyses from other observational studies, should confirm whether similar results are consistently observed.
Conclusions
This analysis of the JAM Trial supports our prespecified hypothesis about hemorrhagic moyamoya disease that both the outcome of nonsurgical treatment and effect of bypass surgery at preventing rebleeding vary with the initial bleeding site. Careful interpretation of the results suggests that patients with posterior hemorrhage are, by its nature, at higher risk and accrue greater benefit from bypass surgery than do those with anterior hemorrhage. Further studies might identify the optimal target group for bypass surgery in hemorrhagic moyamoya disease. 
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